Vol 79, No 1 (2020)
Letter to the Editor
Published online: 2019-08-26
On the assessment of angiogenesis: it is time to change (go further) from an estimate to a measurement
1
, 23, 4
, 23, 4
Abstract
Not available
References
- Fidler IJ, Ellis LM. Neoplastic angiogenesis--not all blood vessels are created equal. N Engl J Med. 2004; 351(3): 215–216.
- Grizzi F, Colombo P, Taverna G, et al. Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol. 2007; 15(2): 134–139.
- Grizzi F, Russo C, Colombo P, et al. Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer. 2005; 5: 14.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–674.
- Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002; 94(12): 883–893.
- Li H, Zhao B, Liu Y, et al. Angiogenesis in residual cancer and roles of HIF-1α, VEGF, and MMP-9 in the development of residual cancer after radiofrequency ablation and surgical resection in rabbits with liver cancer. Folia Morphol. 2019 [Epub ahead of print].
- Morse MA, Sun W, Kim R, et al. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019; 25(3): 912–920.
- Ogunwobi OO, Harricharran T, Huaman J, et al. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol. 2019; 25(19): 2279–2293.
- Taverna G, Grizzi F, Colombo P, et al. Is angiogenesis a hallmark of prostate cancer? Front Oncol. 2013; 3(6): 15–442.
- Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019; 380(15): 1450–1462.
